Open Forum Infectious Diseases, Volume 7, Issue 7, July 2020, ofaa248, https://doi.org/10.1093/ofid/ofaa248
In “Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials”, Open Forum Infectious Diseases, Volume 7, Issue 7, July 2020, ofaa248, few errors occurred in Figure 1 and has been corrected.
Figure 1.
Proportion of placebo-treated participants with rCDI in all participants subset by renal impairment status and in subgroups of participants with prespecified risk factors (Clinical Cure Population). Boxes above bars are differences and 95% confidence intervals. *Clinical Cure Population; †No history of CDI within previous 6 months; ‡History of CDI within previous 6 months; risk factors for rCDI: ≥65 years of age, immunocompromised, history of CDI in previous 6 months, severe CDI (Zar score ≥2), 027 strain.